Skip to main content
. 2018 Dec 12;24(4):563–569. doi: 10.1634/theoncologist.2018-0084

Table 3. Benefit‐risk assessments of atezolizumab and pembrolizumab for first‐line use in cisplatin‐ineligible patients with advanced urothelial carcinoma at the time of initial accelerated approval.

image

Abbreviations: ORR, objective response rate; PD‐1, programmed death receptor‐1; PD‐L1, programmed death‐ligand 1.